JUN 23, 2020 3:24 PM PDT

Psychedelic DMT to Enter Clinical Trials

WRITTEN BY: Annie Lennon

Neuro-pharmaceutical company, MindMed, has announced that it will begin a double-blind placebo-controlled Phase 1 clinical trial to understand how N, N-Dimethyltryptamine (DMT), the primary psychoactive ingredient in Ayahuasca, works in the body. The company ultimately hopes to create therapeutics with the substance to treat mental health conditions like depression and addiction. 

“There is a growing trend in Western society to use Ayahuasca and DMT to facilitate a healing process for one’s mind. However, there is very limited safety data and clinical trials evaluating DMT as a potential medicine so we are going to double down on understanding the therapeutic opportunity and more effective ways to administer DMT in a controlled setting to achieve this healing process.” says JR Rahn, cofounder of MindMed. 

There are currently no approved clinical uses for DMT. The substance has nevertheless been used for centuries, if not longer, by various civilizations and tribes around the world for both its mentally restorative and explorative effects. In the first clinical trial of its kind, the researchers want to establish whether the substance could be engineered for future drug development programs to treat conditions like addiction. 

In partnership with the University Hospital Basel’s Liechti Lab, the researchers from MindMed thus plan to conduct experiments in which patients receive DMT intravenously. Quickly metabolized if taken orally, taking DMT intravenously means that the researchers will both be able to ensure continuous application of the substance, and thus a prolonged DMT experience.

It also means they will be able to stop administration of the substance and the ensuing DMT experience quickly should anything go wrong. In this way, the researchers hope to establish proper dosing during the trial with the goal of inducing a stable DMT experience of between an hour and two hours among patients. 

The study is expected to begin in late 2020, from which the researchers hope to lay the foundations for a future Phase II clinical proof of concept trials. 

 

Sources: MindMed, Bezinga

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
OCT 06, 2020
Cardiology
A New Heart Drug Taken from a Yellow Dye
OCT 06, 2020
A New Heart Drug Taken from a Yellow Dye
Cardiovascular disease is an ever-present issue in the modern world.  One of the most unfortunate cardiovascular ev ...
OCT 20, 2020
Cannabis Sciences
Should Cannabis Doses Be Standardized?
OCT 20, 2020
Should Cannabis Doses Be Standardized?
Should cannabis and its compounds such as tetrahydrocannabinol (THC), the psychoactive compound in cannabis, come in sta ...
OCT 07, 2020
Technology
Millimeter-Precision Drug Delivery
OCT 07, 2020
Millimeter-Precision Drug Delivery
It is almost impossible to deliver targeted drug therapy via the bloodstream without reaching the entire brain and body ...
NOV 02, 2020
Drug Discovery & Development
Beetroot Peptide Shows Promise in Treating Inflammatory Diseases
NOV 02, 2020
Beetroot Peptide Shows Promise in Treating Inflammatory Diseases
Researchers from the Medical Univesity of Vienna in Austria have found that a peptide (a small protein molecule) found i ...
NOV 18, 2020
Drug Discovery & Development
Hepatitis C Drugs May Be Involved Coronavirus Treatment
NOV 18, 2020
Hepatitis C Drugs May Be Involved Coronavirus Treatment
At the present moment, there are no inhibitors that target protease activity of the novel SARS-CoV-2. The main proteases ...
NOV 23, 2020
Drug Discovery & Development
Therapeutically Active Ion-Channels
NOV 23, 2020
Therapeutically Active Ion-Channels
Therapeutically relevant ion channels have inspired researchers to look into drugs that can regulate their activity. Ion ...
Loading Comments...